GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034  Novo announces additional weight-loss in patients switching from injected to oral delivery

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。